SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies.
Markus Hoffmann,Markus Hoffmann,Prerna Arora,Prerna Arora,Rüdiger Groß,Alina Seidel,Bojan F. Hörnich,Alexander S. Hahn,Nadine Krüger,Luise Graichen,Heike Hofmann-Winkler,Amy Kempf,Amy Kempf,Martin Sebastian Winkler,Sebastian R. Schulz,Hans-Martin Jäck,Bernd Jahrsdörfer,Bernd Jahrsdörfer,Hubert Schrezenmeier,Hubert Schrezenmeier,Martin Müller,Alexander Kleger,Jan Münch,Stefan Pöhlmann,Stefan Pöhlmann +24 more
TLDR
In this article, the authors show that SARS-CoV-2/COVID-19 variants B.1.7 (UK), B.351 (South Africa), and P.1 (Brazil) harbor mutations in the viral spike (S) protein that may alter virus-host cell interactions and confer resistance to inhibitors and antibodies.About:
This article is published in Cell.The article was published on 2021-04-29 and is currently open access. It has received 754 citations till now. The article focuses on the topics: Neutralizing antibody.read more
Citations
More filters
Journal ArticleDOI
Mechanisms of SARS-CoV-2 entry into cells.
TL;DR: In this article, structural and cellular foundations for understanding the multistep SARS-CoV-2 entry process, including S protein synthesis, S protein structure, conformational transitions necessary for association of the spike (S) protein with ACE2, engagement of the receptor-binding domain of the S protein with ACS, proteolytic activation of S protein, endocytosis and membrane fusion are provided.
Journal ArticleDOI
The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic
xing feng,Etienne-Emile Baulieu +1 more
TL;DR: In this paper , the authors reported that the Omicron spike was resistant against most therapeutic antibodies but remained susceptible to inhibition by sotrovimab, and that double immunization with BNT162b2 might not adequately protect against severe disease induced by this variant.
Journal ArticleDOI
The biological and clinical significance of emerging SARS-CoV-2 variants.
Kaiming Tao,Philip L Tzou,Janin Nouhin,Ravindra K. Gupta,Tulio de Oliveira,Sergei L Kosakovsky Pond,Daniela Fera,Robert W. Shafer +7 more
TL;DR: The emergence of SARS-CoV-2 variants with novel spike protein mutations that are influencing the epidemiological and clinical aspects of the COVID-19 pandemic has been witnessed as mentioned in this paper.
Journal ArticleDOI
Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review.
TL;DR: In this article, the authors provide an up-to-date comparative analysis of the characteristics, adverse events, efficacy, effectiveness and impact of the variants of concern for nineteen COVID-19 vaccines.
Journal ArticleDOI
Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review
TL;DR: In this paper , the authors provide an up-to-date comparative analysis of the characteristics, adverse events, efficacy, effectiveness and impact of the variants of concern for 19 COVID-19 vaccines.
References
More filters
Posted ContentDOI
LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection
Bryan Edward Jones,Patricia Brown-Augsburger,Kizzmekia S. Corbett,Kathryn Westendorf,Julian Davies,Thomas P. Cujec,Christopher M. Wiethoff,Jamie L. Blackbourne,Beverly A. Heinz,Denisa Foster,Richard E. Higgs,Deepa Balasubramaniam,Lingshu Wang,Roza Bidshahri,Lucas Kraft,Yuri Hwang,Stefanie Zentelis,Kevin R. Jepson,Rodrigo Goya,Maia A. Smith,David Collins,Samuel J. Hinshaw,Sean A. Tycho,Davide Pellacani,Ping Xiang,Krithika Muthuraman,Solmaz Sobhanifar,Marissa H. Piper,Franz J. Triana,Jorg Hendle,A. Pustilnik,Andrew C. Adams,Shawn J. Berens,Ralph S. Baric,David R. Martinez,Robert W. Cross,Thomas W. Geisbert,Viktoriya Borisevich,Olubukola M. Abiona,Hayley M. Belli,Maren de Vries,Adil Mohamed,Meike Dittmann,Marie I. Samanovic,Mark J. Mulligan,Jory A. Goldsmith,Ching-Lin Hsieh,Nicole V. Johnson,Daniel Wrapp,Jason S. McLellan,Bryan C. Barnhart,Barney S. Graham,John R. Mascola,Carl L. Hansen,Ester Falconer +54 more
TL;DR: High-throughput microfluidic screening of antigen-specific B-cells led to the identification of LY-CoV555, a potent anti-spike neutralizing antibody derived from a convalescent COVID-19 patient that protects the upper and lower airways of non-human primates against SARS- CoV-2 infection.
Journal ArticleDOI
Functional analysis of potential cleavage sites in the MERS-coronavirus spike protein
TL;DR: It is found that an intact S1/S2 site was only required for efficient entry into cells expressing endogenous TMPRSS2, and findings suggest that cleavage at S2′ is carried out by proteases recognizing a single arginine, most likely TMPR SS2 and cathepsin L.
Journal ArticleDOI
Differential Sensitivity of Bat Cells to Infection by Enveloped RNA Viruses: Coronaviruses, Paramyxoviruses, Filoviruses, and Influenza Viruses
Markus Hoffmann,Marcel A. Müller,Jan Felix Drexler,Jörg Glende,Meike Erdt,Tim Gützkow,Christoph Losemann,Tabea Binger,Hongkui Deng,Christel Schwegmann-Weßels,Karl Heinz Esser,Christian Drosten,Georg Herrler +12 more
TL;DR: Results indicate that bat cells are more resistant to infection by coronaviruses than to infections by paramyxoviruses, filovirus and influenza viruses, and show a receptor-dependent restriction of the infection of bat cells by CoV.
Journal ArticleDOI
Mutations in the Spike Protein of Middle East Respiratory Syndrome Coronavirus Transmitted in Korea Increase Resistance to Antibody-Mediated Neutralization.
Hannah Kleine-Weber,Hannah Kleine-Weber,Mahmoud Tarek Elzayat,Lingshu Wang,Barney S. Graham,Marcel A. Müller,Christian Drosten,Stefan Pöhlmann,Stefan Pöhlmann,Markus Hoffmann +9 more
TL;DR: Findings indicate that MERS-CoV variants with reduced neutralization sensitivity were transmitted during the Korean outbreak and that the responsible mutations were compatible with robust infection of cells expressing high levels of DPP4.
Journal ArticleDOI
Detection of B.1.351 SARS-CoV-2 Variant Strain - Zambia, December 2020.
Mulenga Mwenda,Ngonda Saasa,Nyambe Sinyange,George B.J. Busby,Peter J. Chipimo,Jason Hendry,Otridah Kapona,Samuel Yingst,Jonas Z Hines,Peter Minchella,Edgar Simulundu,Katendi Changula,King S. Nalubamba,Hirofumi Sawa,Masahiro Kajihara,Junya Yamagishi,Muzala Kapina,Nathan Kapata,Sombo Fwoloshi,Paul M Zulu,Lloyd Mulenga,Simon Agolory,Victor Mukonka,Daniel J. Bridges +23 more
TL;DR: The first laboratory-confirmed cases of coronavirus disease 2019 (COVID-19), the illness caused by SARS-CoV-2, in Zambia were detected in March 2020 (1). Beginning in July, the number of confirmed cases began to increase rapidly, first peaking during July-August, and then declining in September and October as mentioned in this paper.
Related Papers (5)
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
Pengfei Wang,Manoj S. Nair,Lihong Liu,Sho Iketani,Sho Iketani,Yang Luo,Yicheng Guo,Maple Wang,Jian Yu,Baoshan Zhang,Peter D. Kwong,Peter D. Kwong,Barney S. Graham,John R. Mascola,Jennifer Y Chang,Jennifer Y Chang,Michael T. Yin,Michael T. Yin,Magdalena E. Sobieszczyk,Magdalena E. Sobieszczyk,Christos A. Kyratsous,Lawrence Shapiro,Lawrence Shapiro,Zizhang Sheng,Yaoxing Huang,David D. Ho,David D. Ho +26 more
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Fernando P. Polack,Stephen J. Thomas,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Edson D. Moreira,Cristiano Zerbini,Ruth Bailey,Kena A. Swanson,Satrajit Roychoudhury,Kenneth Koury,Ping Li,Warren Kalina,David A. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +28 more
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus.
Bette T. Korber,Will Fischer,Sandrasegaram Gnanakaran,Hyejin Yoon,James Theiler,Werner Abfalterer,Nick Hengartner,Elena E. Giorgi,Tanmoy Bhattacharya,Brian T. Foley,Kathryn M. Hastie,Matthew Parker,David G Partridge,Cariad Evans,Timothy M. Freeman,Thushan I de Silva,Adrienne Angyal,Rebecca Brown,Laura Carrilero,Luke R. Green,Luke R. Green,Luke R. Green,Danielle C. Groves,Katie Johnson,Alexander J Keeley,Benjamin B Lindsey,Paul J. Parsons,Mohammad Raza,Sarah Rowland-Jones,Nikki Smith,Rachel Tucker,Dennis Wang,Matthew Wyles,Charlene McDanal,Lautaro G. Perez,Haili Tang,Alex Moon-Walker,Alex Moon-Walker,Alex Moon-Walker,Sean P. J. Whelan,Celia C. LaBranche,Erica Ollmann Saphire,David C. Montefiori +42 more
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England.
Nicholas G Davies,Sam Abbott,Rosanna C. Barnard,Christopher I Jarvis,Adam J. Kucharski,James D Munday,Carl A. B. Pearson,Timothy W Russell,Damien C. Tully,Alex D. Washburne,Tom Wenseleers,Amy Gimma,William Waites,Kerry L. M. Wong,Kevin van Zandvoort,Justin D. Silverman,Karla Diaz-Ordaz,Ruth H. Keogh,Rosalind M Eggo,Sebastian Funk,Mark Jit,Katherine E. Atkins,Katherine E. Atkins,W. John Edmunds +23 more